Cipla targets US respiratory market growth; submits Symbicort and another generic inhaler | |
Cipla, an Indian pharmaceutical firm, is intensifying its efforts to become a leader in the US market for respiratory medications. The company has filed two generic respiratory drug applications with the US FDA, including a generic version of Symbicort, a medication for asthma and COPD with annual sales exceeding $3 billion. This presents a significant market opportunity for Cipla’s respiratory pipeline. Cipla is also developing several peptide-based respiratory products as part of its speciality drug focus in the US. Cipla’s respiratory products already constitute a major share of its US generics business. Despite recent regulatory challenges, its Albuterol inhalation product continues to maintain market share, demonstrating the strength of Cipla’s position. The company is making progress in resolving previous US regulatory observations related to its manufacturing facilities for respiratory drug production, which have hindered key drug approvals in the past. For more details please visit our website - https://www.medhealthinsight.com/new-soundboard-review-pricing-is-not-always-the-only-criteria-2-9/ ![]() | |
Related Link: Click here to visit item owner's website (0 hit) | |
Target State: New York Target City : New York City Last Update : Sep 17, 2025 2:46 AM Number of Views: 14 | Item Owner : medhealthinsight Contact Email: (None) Contact Phone: (None) |
Friendly reminder: Click here to read some tips. |